Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 7, 2009, Pages 919-927

  Zhang, Qiong ^a   Zhang, Jingfa ^b   Guan, Yuan ^c   Zhang, Shisheng ^a   Zhu, Caihong ^a   Xu, Guo Tong ^b   Wang, Ling ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Aminoguanidine; iNOS; Neovascularization; VEGF

Indexed keywords

AMINOGUANIDINE; BEVACIZUMAB; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; HYPEROXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL; DOWN-REGULATION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FLUORESCEIN ANGIOGRAPHY; GUANIDINES; IMMUNOHISTOCHEMISTRY; INJECTIONS; MICE; NITRIC OXIDE SYNTHASE TYPE II; OXYGEN; RETINA; RETINAL NEOVASCULARIZATION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 67349115693     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1066-x     Document Type: Article

References (41)

1. Zhang SX, Ma JX (2007) Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 26:1-37, doi: 10.1016/j.preteyeres.2006.09.002
2. Arjamaa O, Nikinmaa M (2006) Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 83:473-483, doi: 10.1016/ j.exer.2006.01.016
3. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538-1544
4. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373-385. doi: 10.1016/S0002-9394(01)01381-2
5. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964-970
6. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66-71
7. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 93:4851-4856, doi: 10.1073/pnas.93.10.4851
8. Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141-148, doi: 10.1007/s10456-007-9069-x
9. Chiou GC (2001) Review: Effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther 17:189-198, doi: 10.1089/ 10807680151125555
10. He T, Xing YQ, Zhao XH, Ai M (2007) Interaction between iNOS and COX-2 in hypoxia-induced retinal neovascularization in mice. Arch Med Res 38:807-815, doi: 10.1016/j.arcmed.2007.05.003
11. He T, Ai M, Zhao XH, Xing YQ (2007) Inducible nitric oxide synthase mediates hypoxia-induced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor expression in oxygen-induced retinopathy. Pathobiology 74:336-343, doi: 10.1159/000110027
12. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M (1998) Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587-596, doi: 10.1093/jnci/90.8.587
13. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-556, doi: 10.2337/diabetes.41.4.552
14. Bryk R, Wolff DJ (1998) Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-iminoethyl)lysine. Biochemistry 37:4844-4852, doi: 10.1021/bi972065t
15. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111
16. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX (2001) Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 44:757-765, doi: 10.1007/s001250051685
17. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L, Cassatella M, Noonan DM, Albini A (2002) Neutrophils as a key cellular target for angiostatin: Implications for regulation of angiogenesis and inflammation. FASEB J 16:267-269
18. Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, Ma JX (2002) Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor: A possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 277:9492-9497, doi: 10.1074/jbc.M108004200
19. Ma JX, Zhang SX, Wang JJ (2005) Down-regulation of angiogenic inhibitors: A potential pathogenic mechanism for diabetic complications. Curr Diabetes Rev 1:183-196, doi: 10.2174/1573399054022839
20. Gao G, Ma J (2002) Tipping the balance for angiogenic disorders. Drug Discov Today 7:171-172, doi: 10.1016/S1359-6446(01)02160-2
21. Drack A (2006) Retinopathy of prematurity. Adv Pediatr 53:211-226, doi: 10.1016/j.yapd.2006.04.010
22. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A (2004) Epidemiology of diabetic retinopathy and macular oedema: A systematic review. Eye 18:963-983, doi: 10.1038/sj.eye.6701476
23. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564-572, doi: 10.1001/archopht.122.7.1019
24. Kocur I, Resnikoff S (2002) Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 86:716-722, doi: 10.1136/ bjo.86.7.716
25. Hernandez C, Simo R (2007) Strategies for blocking angiogenesis in diabetic retinopathy: From basic science to clinical practice. Expert Opin Investig Drugs 16:1209-1226, doi: 10.1517/13543784.16.8.1209
26. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275-278, doi: 10.1097/00006982-200603000-00004
27. Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155-158, doi: 10.1016/j.ajo.2006.02.015
28. van Wijngaarden P, Qureshi SH (2008) Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: A review of current practice. Clin Exp Optom 91:427-437, doi: 10.1111/j.1444-0938.2008.00305.x
29. Dadgostar H, Waheed N (2008) The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 22(6):761-767
30. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study. Am J Ophthalmol 145:249-256, doi: 10.1016/j.ajo.2007.09.031
31. Kaur C, Sivakumar V, Foulds WS (2006) Early response of neurons and glial cells to hypoxia in the retina. Invest Ophthalmol Vis Sci 47:1126-1141, doi: 10.1167/iovs.05-0518
32. Shams N, Ianchulev T (2006) Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 19:335-344
33. Hattenbach LO, Falk B, Nurnberger F, Koch FH, Ohrloff C (2002) Detection of inducible nitric oxide synthase and vascular endothelial growth factor in choroidal neovascular membranes. Ophthalmologica 216:209-214, doi: 10.1159/000059634
34. Sennlaub F, Courtois Y, Goureau O (2001) Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 107:717-725, doi: 10.1172/JCI10874
35. Pipili-Synetos E, Kritikou S, Papadimitriou E, Athanassiadou A, Flordellis C, Maragoudakis ME (2000) Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. Br J Pharmacol 129:207-213, doi: 10.1038/ sj.bjp.0702986
36. Ghiso N, Rohan RM, Amano S, Garland R, Adamis AP (1999) Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest Ophthalmol Vis Sci 40:1033-1039
37. Pyriochou A, Vassilakopoulos T, Zhou Z, Papapetropoulos A (2007) cGMP-dependent and -independent angiogenesis-related properties of nitric oxide. Life Sci 81:1549-1554, doi: 10.1016/j.lfs.2007.09.014
38. Mousa SA, Mousa AS (2004) Angiogenesis inhibitors: Current & future directions. Curr Pharm Des 10:1-9, doi: 10.2174/1381612043453531
39. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276:43836-43841, doi: 10.1074/ jbc.M106534200
40. Yan H, Guo Y, Zhang J, Ding Z, Ha W, Harding JJ (2008) Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. Mol Vis 14:2282-2291
41. Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419:31-40, doi: 10.1016/j.abb.2003.08.013